Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SANDIMMUNE vs GENGRAF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclosporine is a calcineurin inhibitor. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby blocking the dephosphorylation and nuclear translocation of NF-AT, reducing T-cell activation and cytokine production.
Calcineurin inhibitor; binds to cyclophilin, inhibits calcineurin-dependent T-cell activation, preventing nuclear factor of activated T-cells (NF-AT) dephosphorylation and translocation, thereby reducing IL-2 and other cytokine gene transcription.
Prophylaxis of organ rejection in kidney, liver, and heart transplants,Treatment of chronic allograft rejection in kidney, liver, and heart transplants,Severe active rheumatoid arthritis (FDA-approved),Psoriasis (FDA-approved),Off-label: atopic dermatitis, nephrotic syndrome, severe ulcerative colitis, aplastic anemia
Prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants,Treatment of active rheumatoid arthritis (FDA-approved for moderate to severe),Treatment of psoriasis (FDA-approved for severe, recalcitrant cases),Off-label: nephrotic syndrome, aplastic anemia, ulcerative colitis, atopic dermatitis
Initial oral dose: 10-15 mg/kg/day divided q12h, then taper to 5-10 mg/kg/day. IV dose: 5-6 mg/kg/day continuous infusion or divided q12h.
5-15 mg/kg/day orally in divided doses every 12 hours.
Terminal elimination half-life is approximately 8.4 hours (range 6–24 hours) in adults; prolonged in patients with hepatic impairment.
Terminal half-life is approximately 8.4 hours (range 5-18 hours) in adult volunteers; prolonged in hepatic impairment.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. Metabolites are excreted primarily in bile and feces.
Hepatic metabolism primarily via CYP3A4 enzyme; also substrate for CYP3A5. Metabolized to multiple metabolites with variable activity, including AM1 (hydroxylated), AM9 (N-demethylated), and AM4N (cyclized). Undergoes extensive first-pass metabolism.
Primarily biliary/fecal (94% of metabolites); renal elimination is minimal (<6% as unchanged drug and metabolites).
Primarily biliary/fecal (94%); renal excretion accounts for 6% (0.1% unchanged).
90–98% bound, primarily to lipoproteins and albumin.
90-98% bound to plasma proteins, primarily lipoproteins, albumin, and alpha-1-acid glycoprotein.
3–5 L/kg in adults; high distribution indicates extensive tissue binding, including to erythrocytes and lymphocytes.
3.5 L/kg (range 1.2-4.8 L/kg) in renal transplant recipients; distribution is extensive and variable.
Oral: 30% (range 10–60%) due to extensive first-pass metabolism; IV: 100%; ophthalmic: not quantified, minimal systemic absorption.
Oral bioavailability is 30% (range 10-60%), variable due to first-pass metabolism and food effects.
For Cr Cl < 30 m L/min: reduce dose by 25-50%. Monitor serum creatinine closely. Avoid in severe renal impairment unless benefit outweighs risk.
GFR <30 m L/min: reduce dose by 50%.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 25-50%. Monitor cyclosporine levels and hepatic function.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use.
Children: 10-15 mg/kg/day oral divided q12h; IV: 5-6 mg/kg/day. Adjust based on trough levels (target 100-400 ng/m L).
4-10 mg/kg/day orally in divided doses every 12 hours; adjusted to target trough levels.
Start at low end of dosing range due to reduced renal and hepatic function. Monitor renal function and cyclosporine levels, as elderly are more susceptible to nephrotoxicity.
Initiate at lower end of dosing range and titrate based on renal function and drug levels.
Increased susceptibility to infection and possible development of lymphoma and other malignancies. Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Sandimmune.
Increased susceptibility to infection and development of lymphoma and other malignancies, particularly of the skin. Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe cyclosporine.
Nephrotoxicity: Monitor renal function closely; dose-dependent and may progress to chronic nephropathy.,Hepatotoxicity: Elevations in liver enzymes and bilirubin.,Hypertension: Common; may require antihypertensive therapy.,Neurotoxicity: Tremor, convulsions, headache, and other neurological effects.,Hyperkalemia: Risk increases with concurrent use of potassium-sparing diuretics or ACE inhibitors.,Hypomagnesemia: Monitor magnesium levels.,Vaccinations: Live vaccines may be less effective and should be avoided.,Carcinogenesis: Increased risk of skin cancer and lymphoproliferative disorders.
Nephrotoxicity: Monitor renal function regularly; risk increased with high doses, other nephrotoxic drugs, or prolonged use.,Hepatotoxicity: Monitor liver function.,Hypertension: Common; require blood pressure control.,Neurotoxicity: Including tremor, convulsions, headache, and paresthesias.,Hyperkalemia: Monitor serum potassium, especially with potassium-sparing diuretics or ACE inhibitors.,Hypomagnesemia: Supplementation may be required.,Increased risk of infections and lymphoproliferative disorders.,Potential for anaphylactic reactions with IV formulation (due to Cremophor EL).,Carcinogenesis: Especially skin malignancies; minimize UV exposure.
Hypersensitivity to cyclosporine or any component of the formulation,Concurrent use with PUVA or UVB therapy in psoriasis patients (increased risk of skin cancer),Uncontrolled hypertension or malignancy (relative for non-transplant indications)
Hypersensitivity to cyclosporine or any component of the formulation (including Cremophor EL for IV),Uncontrolled hypertension,Malignancy (except non-melanoma skin cancer) in patients with rheumatoid arthritis or psoriasis,Concomitant use with PUVA or UVB therapy, methotrexate, other immunosuppressive agents, or coal tar (for psoriasis patients),Abnormal renal function with uncontrolled hypertension (for psoriasis patients),Pregnancy (category C; additional risk of premature birth and low birth weight)
Avoid grapefruit and grapefruit juice. High-fat meals may reduce absorption; administer consistently with or without food. Do not take with potassium-rich foods or salt substitutes without monitoring.
Grapefruit and grapefruit juice increase cyclosporine levels and must be avoided. High-potassium foods (e.g., bananas, oranges, potatoes) may increase hyperkalemia risk; monitor intake. Avoid St. John's wort as it reduces drug levels.
Cyclosporine is not a major human teratogen. First trimester exposure is not associated with an increased risk of major birth defects, but may increase the risk of preterm birth (28-33 weeks) and low birth weight. Second and third trimester use is associated with increased risk of gestational hypertension, preeclampsia, and fetal growth restriction. Prematurity and transient neonatal immunosuppression have been reported.
First trimester: Cyclosporine crosses the placenta. Limited human data, but no major malformations attributed. Second and third trimesters: Risk of intrauterine growth restriction, prematurity, and low birth weight. Consider risk-benefit; avoid if possible, but may be used if essential.
Cyclosporine is excreted into human breast milk. The milk-to-plasma ratio (M/P) ranges from 0.17 to 1.4, with an average of approximately 0.5. The relative infant dose is estimated to be less than 2% of the maternal weight-adjusted dose. Breastfeeding is generally considered acceptable if maternal levels are maintained within therapeutic range and infant is monitored for potential adverse effects (e.g., immunosuppression).
Cyclosporine is excreted into breast milk. Milk-to-plasma ratio approximately 0.3-0.6. Potential for infant immunosuppression and growth inhibition. Weigh benefits against risks; monitor infant for adverse effects.
Pregnancy induces increased volume of distribution and enhanced clearance of cyclosporine, leading to decreased trough levels. Dose adjustments may be required, especially in the second and third trimesters. Increase dose as needed to maintain therapeutic trough concentrations (typically 100-400 ng/m L, depending on indication). Postpartum, dose should be reduced back to prepregnancy levels due to return of normal clearance.
Pregnancy reduces cyclosporine oral bioavailability and increases clearance; dose may need to be increased by 20-50% to maintain therapeutic trough levels. Frequent level monitoring recommended, especially in third trimester. Postpartum dose reduction likely needed.
Monitor trough levels 12 hours post-dose; target varies by transplant organ (e.g., 200-400 ng/m L for kidney, 250-800 ng/m L for liver early post-transplant). Adjust for hepatic dysfunction; cyclosporine is extensively metabolized by CYP3A4. Avoid live vaccines. Use with caution in renal impairment; dose reduction may be needed. Drug interactions: avoid with potassium-sparing diuretics due to hyperkalemia risk; monitor for gingival hyperplasia and hypertension.
Monitor trough levels (target 100-400 ng/m L) and renal function closely. Calcineurin inhibitors cause nephrotoxicity; dose reduction may be necessary. Avoid use with potassium-sparing diuretics or ACE inhibitors due to hyperkalemia risk. Grapefruit increases levels; avoid coadministration. Remember to adjust dose for hepatic impairment.
Take at the same time every day with a full glass of water, consistently with or without food.,Do not consume grapefruit or grapefruit juice; it can increase cyclosporine levels.,Report signs of infection (fever, sore throat), tremors, or changes in urine output.,Avoid live vaccines (e.g., MMR, nasal flu spray) and contact with recently vaccinated individuals.,Use sunscreen as cyclosporine may increase sensitivity to sunlight.,Do not change brand or dosage form without consulting prescriber.
Take with or without food consistently at the same times each day.,Do not consume grapefruit or grapefruit juice while on this medication.,Report signs of infection, tremors, or changes in urine output immediately.,Avoid live vaccinations and limit sun exposure due to increased skin cancer risk.,Do not stop or change dose without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SANDIMMUNE vs GENGRAF, answered by our medical review team.
SANDIMMUNE is a Calcineurin Inhibitor that works by Cyclosporine is a calcineurin inhibitor. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby blocking the dephosphorylation and nuclear translocation of NF-AT, reducing T-cell activation and cytokine production.. GENGRAF is a Calcineurin Inhibitor Immunosuppressant that works by Calcineurin inhibitor; binds to cyclophilin, inhibits calcineurin-dependent T-cell activation, preventing nuclear factor of activated T-cells (NF-AT) dephosphorylation and translocation, thereby reducing IL-2 and other cytokine gene transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SANDIMMUNE and GENGRAF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SANDIMMUNE is: Initial oral dose: 10-15 mg/kg/day divided q12h, then taper to 5-10 mg/kg/day. IV dose: 5-6 mg/kg/day continuous infusion or divided q12h.. The standard adult dose of GENGRAF is: 5-15 mg/kg/day orally in divided doses every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SANDIMMUNE and GENGRAF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SANDIMMUNE is classified as Category C. Cyclosporine is not a major human teratogen. First trimester exposure is not associated with an increased risk of major birth defects, but may increase the risk of preterm birth (2. GENGRAF is classified as Category C. First trimester: Cyclosporine crosses the placenta. Limited human data, but no major malformations attributed. Second and third trimesters: Risk of intrauterine growth restriction,. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.